🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against superbug strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with figures suggesting in excess of 82 million instances each year. Particularly high rates are reported in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the reality of rising global incidence, escalating drug resistance and the highly restricted treatment choices currently available.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The global health body has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists believe that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is employed against urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This authorization represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Results and Worldwide Availability

Based on data published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which combines a dual-drug approach. The study involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in numerous regions with limited resources.

Medical professionals treating patients have voiced positive views. Having a one-pill regimen such as this is described as a "critical tool" for public health efforts. This is deemed crucial to reduce the burden of the disease for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.